PDF(Pubmed)
Abstract：
In 2008, bacilli from 2 Hansen disease (leprosy) cases were identified as a new species, Mycobacterium lepromatosis. We conducted a systematic review of studies investigating M. lepromatosis as a cause of HD. Twenty-one case reports described 27 patients with PCR-confirmed M. lepromatosis infection (6 dual M. leprae/M. lepromatosis): 10 case-patients in the United States (7 originally from Mexico), 6 in Mexico, 3 in the Dominican Republic, 2 each in Singapore and Myanmar, and 1 each in Indonesia, Paraguay, Cuba, and Canada. Twelve specimen surveys reported 1,098 PCR-positive findings from 1,428 specimens, including M. lepromatosis in 44.9% (133/296) from Mexico, 3.8% (5/133) in Colombia, 12.5% (10/80) in Brazil, and 0.9% (2/224) from the Asia-Pacific region. Biases toward investigating M. lepromatosis as an agent in cases of diffuse lepromatous leprosy or from Mesoamerica precluded conclusions about clinicopathologic manifestations and geographic distribution. Current multidrug treatments seem effective for this infection.
摘要：
2008年，来自2例汉森病（麻风病）病例的杆菌被确定为新物种，麻木病分枝杆菌。我们对作为HD病因的研究进行了系统评价。21例病例报告描述了27例PCR证实的麻风分枝杆菌感染患者（6例双重麻风分枝杆菌/M。麻风病）：10例患者在美国（7例最初来自墨西哥），6墨西哥,3在多米尼加共和国，新加坡和缅甸各2个，印度尼西亚各1个，巴拉圭,古巴,和加拿大。十二项样本调查报告了1,428份样本中的1,098份PCR阳性结果，包括墨西哥的44.9%(133/296)的麻风分枝杆菌，3.8%（5/133）在哥伦比亚，巴西12.5%（10/80），和0.9%（2/224）来自亚太地区。在弥漫性麻风病或来自中美洲的情况下，研究麻风病分枝杆菌作为药物的偏见排除了有关临床病理表现和地理分布的结论。目前的多药治疗似乎对这种感染有效。
